Show simple item record

dc.contributor.authorParker, C
dc.contributor.authorNilsson, S
dc.contributor.authorHeinrich, D
dc.contributor.authorHelle, S
dc.contributor.authorO'Sullivan, J
dc.contributor.authorFosså, S
dc.contributor.authorChodacki, A
dc.contributor.authorWiechno, P
dc.contributor.authorLogue, John P
dc.contributor.authorSeke, M
dc.contributor.authorWidmark, A
dc.contributor.authorJohannessen, D
dc.contributor.authorHoskin, P
dc.contributor.authorBottomley, D
dc.contributor.authorJames, N
dc.contributor.authorSolberg, A
dc.contributor.authorSyndikus, I
dc.contributor.authorKliment, J
dc.contributor.authorWedel, S
dc.contributor.authorBoehmer, S
dc.contributor.authorDall'Oglio, M
dc.contributor.authorFranzén, L
dc.contributor.authorColeman, R
dc.contributor.authorVogelzang, N
dc.contributor.authorO'Bryan-Tear, C
dc.contributor.authorStaudacher, K
dc.contributor.authorGarcia-Vargas, J
dc.contributor.authorShan, M
dc.contributor.authorBruland, Ø
dc.contributor.authorSartor, O
dc.date.accessioned2013-09-25T13:44:55Z
dc.date.available2013-09-25T13:44:55Z
dc.date.issued2013-07-18
dc.identifier.citationAlpha emitter radium-223 and survival in metastatic prostate cancer. 2013, 369 (3):213-23 N Engl J Meden_GB
dc.identifier.issn1533-4406
dc.identifier.pmid23863050
dc.identifier.doi10.1056/NEJMoa1213755
dc.identifier.urihttp://hdl.handle.net/10541/302266
dc.description.abstractRadium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen_GB
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBone Neoplasms
dc.subject.meshDouble-Blind Method
dc.subject.meshHumans
dc.subject.meshIsotopes
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProstatic Neoplasms
dc.subject.meshRadium
dc.titleAlpha emitter radium-223 and survival in metastatic prostate cancer.en
dc.typeArticleen
dc.contributor.departmentRoyal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom.en_GB
dc.identifier.journalNew England Journal of Medicineen_GB
html.description.abstractRadium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.


This item appears in the following Collection(s)

Show simple item record